Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Sponsor
Chinese Academy of Medical Sciences
Study ID
NCT02995187
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a Single-center, Open-label, Single-arm,Non-randomized exploratory clinical trial evaluating the efficacy and safety of Apatinib for third-line and later treatment of patients with small cell lung cancer.

Key Dates

Start date
Dec 31, 2016
Status verified
Sep 2017
Primary completion
May 31, 2018
Completion
Sep 30, 2018

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Mesylate tablet
    Patients received oral apatinib 500 mg in tablet once daily, a treatment cycle was defined as 28 days (4 weeks).

Primary Outcome Measure

Progression-free survival [ Time Frame: up to 3 years ]

Central Contacts

Related Studies